Geranium sanguineum for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 25 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Geranium sanguineum may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 11,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed Geranium sanguineum in detail.

Studies suggesting benefit with Geranium sanguineum

Vahekeni et al., Historical texts as a potential resource for plant-based antiviral agents against SARS-CoV-2: the example of the Receptarium of Burkhard III von Hallwyl from 16th-century Switzerland, Frontiers in Pharmacology, doi:10.3389/fphar.2025.1731629

Background In search for effective prophylactic and possibly curative therapeutics against SARS-CoV-2, an historical-ethnopharmacological approach was used to select plants described in the Receptarium of Burkhard III von Hallwyl (RBH), a recipe text from 16th century Switzerland. Ten plant species were selected from the pre-established RBH database based on specific historical uses presumably linked with the treatment of viral infections. Methods From each plant aqueous and hydroethanolic extracts were produced. CellTiter-Glo® Luminescent Cell Viability Assay was used to assess antiviral activity against SARS-CoV-2 and the effect on cell viability of the extracts. Results Of the ten plants tested, four displayed an antiviral activity ≥ 50% at 16.7 μg/ml with acceptable cell viability (&gt; 75%): Artemisia vulgaris L. (aerial parts), Geranium robertianum L. (arial parts), Sambucus nigra L. (leaves) and Viola odorata L. (leaves). The crude extracts were partitioned in aqueous and organic pre-fractions and further analyzed. The ethyl acetate pre-fractions of G. robertianum, S. nigra , and V. odorata expressed significant antiviral activity of nearly 100% at 5.6 μg/ml (P &lt; 0.05). The most potent inhibitory activity was observed for the ethyl acetate pre-fraction of the leaves of Viola odorata with 87% at 1.9 μg/ml (P &lt; 0.0001). Alongside bioactivity testing, phytochemical fingerprints were made, with the aim to provide a preliminary characterization of the active crude extracts. An overview of published phytochemical and antiviral data on the four active plants reveals a fragmentary picture, especially when considering the plant parts investigated. Despite of the promising antiviral effects observed in our study, further in-depth pharmacological and phytochemical investigations are required to comprehensively evaluate the potential of our candidates. Conclusions Our study suggests that an ethnopharmacological approach based on historical records of plant use in combination with a rational selection and testing procedure allows to identify interesting candidates, even among medicinal plants no longer in use. The process of selecting plants from RBH also illustrates the challenges associated with the study of historical texts, particularly the interpretation of the medicinal uses and the assessment of the botanical..

Abarova et al., Emerging Therapeutic Potential of Polyphenols from Geranium sanguineum L. in Viral Infections, Including SARS-CoV-2, Biomolecules, doi:10.3390/biom14010130

The existing literature supports the anti-inflammatory, antioxidant, and antiviral capacities of the polyphenol extracts derived from Geranium sanguineum L. These extracts exhibit potential in hindering viral replication by inhibiting enzymes like DNA polymerase and reverse transcriptase. The antiviral properties of G. sanguineum L. seem to complement its immunomodulatory effects, contributing to infection resolution. While preclinical studies on G. sanguineum L. suggest its potential effectiveness against COVID-19, there is still a lack of clinical evidence. Therefore, the polyphenols extracted from this herb warrant further investigation as a potential alternative for preventing and treating COVID-19 infections.